Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is ...

Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons,” published in the November 2024 issue of Infectious ...

In the PURPOSE 2 trial, lenacapavir offered almost complete protection to cisgender men, transgender women, transgender men, ...

A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

Ahead of World AIDS Day, Unitaid is announcing a US$22 million investment to accelerate the introduction and access to ...

Discover the groundbreaking results of Lenacapavir, a twice-yearly injection that reduces HIV infection risk offering an ...

The shot was 100% effective in preventing HIV infections in a study of women, and results published Wednesday show it worked ...